Long-Term Contingent Consideration Payable (Details) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Business Acquisition, Contingent Consideration [Line Items]
Additions		$ 7,695
Payments to Related Parties		(9,106)
Operating Expense; Acquisition-Related		7,916	$ 5,254
Interest Expense; Financing-Related		1,861
Total contingent consideration		131,059		$ 122,693
Less: Current portion		28,403		28,614
Total long-term contingent consideration payable		102,656		$ 94,079
Warrant [Member] | Acquisition-related Costs [Member]
Business Acquisition, Contingent Consideration [Line Items]
Business Combination,Beginning	[1]	20,617
Additions	[1]	0
Payments to Related Parties	[1]	0
Operating Expense; Acquisition-Related	[1]	(3,535)
Interest Expense; Financing-Related	[1]	0
Business Combination,Ending	[1]	17,082
Earn Out Payments [Member] | Acquisition-related Costs [Member]
Business Acquisition, Contingent Consideration [Line Items]
Business Combination,Beginning	[2]	90,468
Additions	[2]	0
Payments to Related Parties	[2]	(8,014)
Operating Expense; Acquisition-Related	[2]	11,451
Interest Expense; Financing-Related	[2]	0
Business Combination,Ending	[2]	93,905
Deerfield Royalty agreement [Member] | Financing Related Costs [Member]
Business Acquisition, Contingent Consideration [Line Items]
Business Combination,Beginning	[3]	7,862
Additions	[3]	0
Payments to Related Parties	[3]	(739)
Operating Expense; Acquisition-Related	[3]	0
Interest Expense; Financing-Related	[3]	1,038
Business Combination,Ending	[3]	8,161
Broadfin Royalty agreement [Member] | Financing Related Costs [Member]
Business Acquisition, Contingent Consideration [Line Items]
Business Combination,Beginning	[4]	3,746
Additions	[4]	0
Payments to Related Parties	[4]	(353)
Operating Expense; Acquisition-Related	[4]	0
Interest Expense; Financing-Related	[4]	496
Business Combination,Ending	[4]	3,889
FSC Royalty Agreement [Member] | Financing Related Costs [Member]
Business Acquisition, Contingent Consideration [Line Items]
Business Combination,Beginning	[5]	0
Additions	[5]	7,695
Payments to Related Parties	[5]	0
Operating Expense; Acquisition-Related	[5]	0
Interest Expense; Financing-Related	[5]	327
Business Combination,Ending	[5]	$ 8,022

[1] As part of the consideration for the Company’s acquisition of Éclat Pharmaceuticals, LLC on March 13, 2012, the Company issued two warrants with a six-year term which allow for the purchase of a combined total of 3,300 ordinary shares of Flamel. One warrant is exercisable for 2,200 shares at an exercise price of $7.44 per share, and the other warrant is exercisable for 1,100 shares at an exercise price of $11.00 per share.

[2] As part of the consideration for the Company’s acquisition of Éclat Pharmaceuticals, LLC in March 2012, the Company committed to provide quarterly earn-out payments equal to 20% of any gross profit generated by certain Éclat Pharmaceuticals products. These payments will continue in perpetuity, to the extent revenues of the related product also continue in perpetuity.

[3] As part of a February 2013 debt financing transaction conducted with Deerfield Management, a related party and current shareholder, the Company received cash of $2,600 in exchange for entering into a royalty agreement whereby the Company shall pay quarterly a 1.75% royalty on the net sales of certain Éclat Pharmaceuticals products until December 31, 2024.

[4] As part of a December 2013 debt financing transaction conducted with Broadfin Healthcare Master Fund, a related party and current shareholder, the Company received cash of $2,200 in exchange for entering into a royalty agreement whereby the Company shall pay quarterly a 0.834% royalty on the net sales of certain Éclat Pharmaceuticals products until December 31, 2024.

[5] As part of the consideration for the Company’s acquisition of FSC Holdings, LLC in February 2016, the Company entered into a royalty agreement whereby the Company shall pay quarterly a 15% royalty on the net sales of certain FSC products, up to $12,500 for a period not exceeding ten years.